Catalyst Wire Dossier Catalyst Wire Dossier

Belvarafenib

belvarafenib · Genentech, Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Belvarafenib, covering 2026-03-04 to 2026-03-30. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. [Phase 1]

See pricing